Table 2. Survival at 5 and 10 years according to the number of biomarkers elevated.
| Biomarkers elevated | Patients | 5 year survival | 10 year survival | ||
|---|---|---|---|---|---|
| Total no. (%) |
NYHA I/II no. (%) |
NYHA III/IV no. (%) |
|||
| Overall | 665 (100%) | 359 (54%) | 306 (46%) | 82% (79%, 85%) | 55% (50%, 59%) |
| 0 | 27 (4%) | 16 (4%) | 11 (4%) | 96% (76%, 99%) | 73% (46%, 88%) |
| 1 | 81 (12%) | 52 (15%) | 29 (10%) | 88% (79%, 94%) | 77% (63%, 86%) |
| 2 | 111 (17%) | 63 (18%) | 48 (16%) | 92% (85%, 96%) | 66% (55%, 76%) |
| 3 | 122 (18.5%) | 77 (22%) | 45 (15%) | 85% (77%, 90%) | 64% (54%, 73%) |
| 4 | 108 (16.5%) | 56 (16%) | 52 (17%) | 79% (69%, 86%) | 42% (30%, 55%) |
| 5 | 89 (13.5%) | 46 (13%) | 43 (14%) | 76% (65%, 84%) | 43% (31%, 54%) |
| 6 | 74 (11%) | 33 (9%) | 41 (14%) | 74% 62%, 82%) | 41% (29%, 54%) |
| 7 | 46 (7%) | 14 (4%) | 32 (11%) | 67% (51%, 78%) | 29% (15%, 45%) |
|
Elevated biomarker categories |
|||||
| 0–1 | 108 (16%) | 68 (19%) | 40 (13%) | 90% (83%, 95%) | 76% (64%, 84%) |
| 2–3 | 233 (35%) | 140 (39%) | 93 (31%) | 88% (83%, 92%) | 65% (58%, 72%) |
| 4–6 | 271 (41%) | 135 (38%) | 136 (45%) | 76% (71%, 81%) | 42% (35%, 49%) |
| 7 | 46 (7%) | 14 (4%) | 32 (11%) | 67% (51%, 78%) | 29% (15%, 45%) |
Abbreviations: NYHA, New York Heart Association